Millennial Closes "Bought Deal" LIFE Offering of $17,537,500 and Concurrent Non-Brokered Private Placement for Total Proceeds of $18,287,500
aTyr PharmaaTyr Pharma(US:LIFE) TMX Newsfile·2026-01-29 13:41

Core Viewpoint - Millennial Potash Corp. has successfully closed a "bought deal" private placement offering, raising gross proceeds of $17,537,500 through the sale of 5,750,000 units at a price of $3.05 per unit, which includes a 15% over-allotment option exercised by underwriters [1][2]. Group 1: Offering Details - The LIFE Offering was led by Cantor Fitzgerald Canada Corporation as the lead underwriter and sole bookrunner [2]. - Concurrently, the company closed a non-brokered private placement offering of 245,901 additional units at the same offering price, generating an additional $750,000 in gross proceeds [3]. - Each unit from both offerings consists of one common share and one-half of a common share purchase warrant, with each full warrant allowing the purchase of one common share at an exercise price of $4.00 for 36 months [4]. Group 2: Use of Proceeds - The net proceeds from the offerings will be allocated towards the costs of a definitive feasibility study for the Banio Potash Project and for general working capital [5]. Group 3: Regulatory and Compliance Information - The LIFE Units were issued under specific Canadian securities regulations and are not subject to a hold period, while the Non-LIFE Units are subject to a four-month resale restriction [6][7]. - The company paid the underwriters a cash commission of $1,052,250 and issued non-transferable compensation options for the purchase of up to 230,000 common shares at the offering price until January 29, 2029 [8]. Group 4: Company Statements - The Chairman of Millennial Potash Corp. expressed satisfaction with the completion of the LIFE offering, highlighting the confidence from leading global asset management firms in the company's progress and development plans [11].